Biopharma SHAKTI

Biopharma SHAKTI Latest News

Recently, the Union Minister for Finance announced the launch of Biopharma Shakti initiative in budget 2026-27.

About Biopharma SHAKTI

• ‘Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology & Innovation)’ is designed to develop India into a global biopharmaceutical manufacturing hub.
• This will build the ecosystem for domestic production of biologics and biosimilars. 
• It will include a Biopharma-focused network with 3 new National Institutes of Pharmaceutical Education and Research (NIPER) and upgrading 7 existing ones.
• It will also create a network of over 1000 accredited India Clinical Trials sites.
• Financial Outlay & Time Period: ₹10,000 crore over the next five years
• This initiative will catalyse investments in advanced biomanufacturing infrastructure, promote innovation and enhance India’s capabilities in high-value, next-generation therapies.
• It will focus on building a biopharma-centric innovation and manufacturing network, responding to India’s rapidly changing disease profile marked by a rising burden of non-communicable diseases such as diabetes, cancer and autoimmune disorders.

What is Biologics?

• Biologics are complex medicines derived from living organisms.
• Their complex manufacturing processes have traditionally limited their availability, primarily serving high-income countries.

What are Biosimilars?

• These are highly similar versions of biologic medicines, developed through comprehensive analytical studies and rigorous preclinical and clinical trials to ensure therapeutic equivalence.
• These products offer equally effective and safe alternatives thereby increasing market competition and reducing the costs of biologic therapies.

Source: PIB

‹ ›